This inventor holds 1 USPTO granted patent. Top assignee: Amgen Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Greg Flynn - Innovator in Antibody Variants
Introduction
Greg Flynn is a notable inventor recognized for his contributions to the field of biotechnology. He has made significant strides in the development of antibody variants, particularly in relation to sclerostin.
Latest Patents
Greg Flynn holds a patent for "C-Terminal Anti-Sclerostin Antibody Variants." This innovation showcases his expertise in creating targeted therapies that can potentially improve treatment options for various conditions.
Career Highlights
Flynn is currently employed at Amgen Inc., a leading biotechnology company known for its focus on innovative medicines. His work at Amgen has allowed him to contribute to groundbreaking research and development in the field.
Collaborations
Throughout his career, Greg has collaborated with talented individuals such as Zhe Huang and Jennitte LeAnn Stevens. These partnerships have fostered a creative environment that encourages the advancement of scientific knowledge.
Conclusion
Greg Flynn's work in developing antibody variants exemplifies the impact of innovation in biotechnology. His contributions continue to shape the future of medical treatments and therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile